(24/7 MARKET NEWS) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) reported, after yesterday’s market close, that additional follow-up data from Jasper’s investigator-sponsored study of briquilimab as a conditioning agent in the treatment of sickle cell disease (SCD) were presented in a plenary session focused on novel antibody-based conditioning regimens at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.
- First two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-up
- Third sickle cell disease participant has now achieved 100% donor myeloid chimerism through 30 days follow-up
- All three participants have increased their hemoglobin at last follow-up relative to baseline
Jasper Therapeutics is at $1.96, up $0.13 (+7.10%), on trading volume of 450 thousand premarket shares.
Its 52-week trading range is $0.3862 to $5.39. It looks like it must plow through several resistance points, but, if it can break through the $2.50 inflection point, on stronger volume, it may try to challenge its February 2022 trading levels..
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.